Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,200 peer-reviewed publications.

The CPRD bibliography is updated on a monthly basis (last updated 4 July 2019) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

(PDF, 3MB, 185 pages)

 

Export 35 results:
[ Author(Asc)] Title Type Year
Filters: Author is van Staa, T. P.  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
V
T. P. van Staa, Carr, D. F., O'Meara, H., McCann, G., and Pirmohamed, M., Predictors and outcomes of increases in creatine phosphokinase concentrations or rhabdomyolysis risk during statin treatment, Br J Clin Pharmacol, vol. 78, pp. 649-59, 2014.
T. P. van Staa, Dyson, L., McCann, G., Padmanabhan, S., Belatri, R., Goldacre, B., Cassell, J., Pirmohamed, M., Torgerson, D., Ronaldson, S., Adamson, J., Taweel, A., Delaney, B., Mahmood, S., Baracaia, S., Round, T., Fox, R., Hunter, T., Gulliford, M., and Smeeth, L., The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials, Health Technol Assess, vol. 18, pp. 1-146, 2014.
T. P. van Staa, Gulliford, M., Ng, E. S., Goldacre, B., and Smeeth, L., Prediction of cardiovascular risk using Framingham, ASSIGN and QRISK2: how well do they predict individual rather than population risk?, PLoS One, vol. 9, p. e106455, 2014.
T. P. van Staa, Abenhaim, L., Cooper, C., Zhang, B., and Leufkens, H. G., The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results, Pharmacoepidemiol Drug Saf, vol. 9, pp. 359-66, 2000.
T. P. van Staa, Leufkens, H. G., Abenhaim, L., Begaud, B., Zhang, B., and Cooper, C., Use of oral corticosteroids in the United Kingdom, Qjm, vol. 93, pp. 105-11, 2000.
T. P. van Staa, Leufkens, H. G., Abenhaim, L., Zhang, B., and Cooper, C., Use of oral corticosteroids and risk of fractures, J Bone Miner Res, vol. 15, pp. 993-1000, 2000.
T. P. van Staa, Leufkens, H. G., and Cooper, C., Use of nonsteroidal anti-inflammatory drugs and risk of fractures, Bone, vol. 27, pp. 563-8, 2000.
T. P. van Staa, Leufkens, H. G., Abenhaim, L., Zhang, B., and Cooper, C., Oral corticosteroids and fracture risk: relationship to daily and cumulative doses, Rheumatology (Oxford), vol. 39, pp. 1383-9, 2000.
T. P. van Staa, Abenhaim, L., Cooper, C., Zhang, B., and Leufkens, H. G., Public health impact of adverse bone effects of oral corticosteroids, Br J Clin Pharmacol, vol. 51, pp. 601-7, 2001.
T. P. van Staa, Dennison, E. M., Leufkens, H. G., and Cooper, C., Epidemiology of fractures in England and Wales, Bone, vol. 29, pp. 517-22, 2001.
T. P. van Staa, Leufkens, H. G., and Cooper, C., Use of inhaled corticosteroids and risk of fractures, J Bone Miner Res, vol. 16, pp. 581-8, 2001.
T. P. van Staa, Wegman, S., de Vries, F., Leufkens, B., and Cooper, C., Use of statins and risk of fractures, Jama, vol. 285, pp. 1850-5, 2001.
T. P. van Staa, Leufkens, H. G., and Cooper, C., Does a fracture at one site predict later fractures at other sites? A British cohort study, Osteoporos Int, vol. 13, pp. 624-9, 2002.
T. P. van Staa, Leufkens, H. G., and Cooper, C., Utility of medical and drug history in fracture risk prediction among men and women, Bone, vol. 31, pp. 508-14, 2002.
T. P. van Staa, Selby, P., Leufkens, H. G., Lyles, K., Sprafka, J. M., and Cooper, C., Incidence and natural history of Paget's disease of bone in England and Wales, J Bone Miner Res, vol. 17, pp. 465-71, 2002.
T. P. van Staa, Boulton, F., Cooper, C., Hagenbeek, A., Inskip, H., and Leufkens, H. G., Neutropenia and agranulocytosis in England and Wales: incidence and risk factors, Am J Hematol, vol. 72, pp. 248-54, 2003.
T. P. van Staa, Cooper, C., Leufkens, H. G., and Bishop, N., Children and the risk of fractures caused by oral corticosteroids, J Bone Miner Res, vol. 18, pp. 913-8, 2003.
T. P. van Staa, Cooper, C., Leufkens, H. G., Lammers, J. W., and Suissa, S., The use of inhaled corticosteroids in the United Kingdom and the Netherlands, Respir Med, vol. 97, pp. 578-85, 2003.
T. P. van Staa, Bishop, N., Leufkens, H. G., and Cooper, C., Are inhaled corticosteroids associated with an increased risk of fracture in children?, Osteoporos Int, vol. 15, pp. 785-91, 2004.
T. P. van Staa, Travis, S., Leufkens, H. G., and Logan, R. F., 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study, Gastroenterology, vol. 126, pp. 1733-9, 2004.
T. P. van Staa, Card, T., Logan, R. F., and Leufkens, H. G., 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study, Gut, vol. 54, pp. 1573-8, 2005.
T. P. van Staa, Geusens, P., Pols, H. A., de Laet, C., Leufkens, H. G., and Cooper, C., A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids, Qjm, vol. 98, pp. 191-8, 2005.
T. P. van Staa, Geusens, P., Bijlsma, J. W., Leufkens, H. G., and Cooper, C., Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis, Arthritis Rheum, vol. 54, pp. 3104-12, 2006.
T. P. van Staa, Geusens, P., Zhang, B., Leufkens, H. G., Boonen, A., and Cooper, C., Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids, Rheumatology (Oxford), vol. 46, pp. 460-6, 2007.
T. P. van Staa, Cooper, C., Barlow, D., and Leufkens, H. G., Individualizing the risks and benefits of postmenopausal hormone therapy, Menopause, vol. 15, pp. 374-81, 2008.
T. P. van Staa, Rietbrock, S., Setakis, E., and Leufkens, H. G., Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?, J Intern Med, vol. 264, pp. 481-92, 2008.
T. P. van Staa, Smeeth, L., Persson, I., Parkinson, J., and Leufkens, H. G., Evaluating drug toxicity signals: is a hierarchical classification of evidence useful or a hindrance?, Pharmacoepidemiol Drug Saf, vol. 17, pp. 475-84, 2008.
T. P. van Staa, Smeeth, L., Persson, I., Parkinson, J., and Leufkens, H. G., What is the harm-benefit ratio of Cox-2 inhibitors?, Int J Epidemiol, vol. 37, pp. 405-13, 2008.
T. P. van Staa, Leufkens, H. G., Zhang, B., and Smeeth, L., A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example, PLoS Med, vol. 6, p. e1000194, 2009.
T. P. van Staa and Sprafka, J. M., Study of adverse outcomes in women using testosterone therapy, Maturitas, vol. 62, pp. 76-80, 2009.
T. P. van Staa, Setakis, E., Di Tanna, G. L., Lane, D. A., and Lip, G. Y., A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice, J Thromb Haemost, vol. 9, pp. 39-48, 2011.
T. P. van Staa, Patel, D., Gallagher, A. M., and De Bruin, M. L., Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data, Diabetologia, vol. 55, pp. 654-65, 2012.
T. P. van Staa, Smeeth, L., Ng, E. S., Goldacre, B., and Gulliford, M., The efficiency of cardiovascular risk assessment: do the right patients get statin treatment?, Heart, vol. 99, pp. 1597-602, 2013.
T. P. van Staa, Abenhaim, L., and Cooper, C., Use of cyclical etidronate and prevention of non-vertebral fractures, Br J Rheumatol, vol. 37, pp. 87-94, 1998.
T. P. van Staa, Leufkens, H., Abenhaim, L., and Cooper, C., Postmarketing surveillance of the safety of cyclic etidronate, Pharmacotherapy, vol. 18, pp. 1121-8, 1998.
[Page last reviewed 4 July 2019]